Sign inJoin waitlistJoin the waitlist

Joseph Caster

Associate Professor, Department of Radiation Oncology · SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY

Credentials: · · · · · ·

History

SIDNEY KIMMEL MEDICAL COLLEGE AT THOMAS JEFFERSON UNIVERSITY
Present
Univ of Maryland Sch of Med
Present
University of North Carolina Hospitals
Present

Radiation Oncology
University of North Carolina Hospitals
2013–2017
University of North Carolina School of Medicine
2012–2013
Duke University
University of North Carolina at Chapel Hill School of Medicine
2008–2012
Florida State University
2004–2008

Research

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Nature Nanotechnology · 2017 · 527 citations
Clinical Translation of Nanomedicine
Review · Chemical Reviews · 2015 · 526 citations
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
Review · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · 2017 · First of 4 authors · 244 citations

Andrew Wang
19 papers
Bryan Allen
10 papers
Steven Seyedin
7 papers · 6 as a resident
Tian Zhang
7 papers · 2 as a fellow
John Buatti
6 papers
KR
Kyle Roche
5 papers
Joel Tepper
4 papers
ME
Michael Eblan
4 papers · 2 as a resident
Daniel Berg
3 papers
EW
Edina Wang
3 papers
Joseph Cullen
3 papers
Quentin Adams
3 papers · 2 as a resident

Clinical trials

A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients
Principal investigator · Withdrawn · Phase 2
Joseph J. Cullen, MD, FACS
2025–2030
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Principal investigator · Terminated · Phase 1
University of Iowa
2022–2025
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2030